Prostate Cancer Treatment Guidelines

Introduction to Prostate Cancer Treatment

Prostate cancer treatment guidelines are established by various authorities, including the American Urological Association and the Prostate Cancer Working Group, to standardize care and improve patient outcomes 1, 2, 3

Following radiation therapy, PSA values should fall to a low level and then remain stable, with PSA values < 0.2 ng/mL being uncommon after external beam radiotherapy, which does not ablate all prostate tissue, according to the American Urological Association 3
Biochemical recurrence is defined as a rise in PSA level of 2.0 ng/ml or more above the nadir, after radiation therapy, as per the American Urological Association guidelines 3
"PSA bounces" can occur after radiation therapy, particularly with brachytherapy, and should not be mistaken for disease progression, as noted by the American Urological Association 3
For patients with metastatic disease receiving androgen suppression therapy, failure to achieve a PSA nadir < 4.0 ng/mL seven months after initiation is associated with shorter survival, as recommended by the American Urological Association 3

Early PSA changes (within 12 weeks) should not be used for clinical decision making, as they may not accurately predict long-term outcomes, according to the Prostate Cancer Working Group 2
PSA changes should not be used as the sole indicator of clinical benefit, as they have not met the criteria for surrogacy in predicting long-term outcomes such as delaying metastases or prolonging life, according to the Journal of Clinical Oncology 1
A minimum exposure of 12 weeks is recommended before making definitive conclusions about treatment efficacy, as stated by the Prostate Cancer Working Group 2
Various PSA patterns can occur after treatment initiation, including continued rise before decline, plateau, or delayed response, as reported in the Journal of Clinical Oncology 1
The overall clinical picture, including symptoms and imaging findings, is more important than PSA changes alone, as emphasized by the Journal of Clinical Oncology and The Journal of Urology 1, 3
PSMA PET/CT may be particularly valuable for monitoring response to LU-177 therapy, as suggested by the Journal of Clinical Oncology 4
Relying solely on early PSA changes may lead to premature discontinuation of potentially effective therapy, as warned by the Prostate Cancer Working Group 2
PSA decline does not always correlate with improved survival or delayed progression, as noted in the Journal of Clinical Oncology 1